ALZHEIMER’S ASSOCIATION AWARDS $4.3 MILLION TO ACCELERATE THE LAUNCH OF NEW DRUG TREATMENT ARMS IN LANDMARK PREVENTION TRIAL

If we had anything even remotely close to a great stroke association they would be getting foundation grants to solve one of the BHAGs (Big Hairy Audacious Goals)  Like repeatable neuroplasticity, repeatable neurogenesis, fatigue, spasticity, aphasia. And since we have no National Stroke Plan or strategy nothing will get done in stroke that actually helps survivors.
http://www.alz.org/documents_custom/dia-tu_nextgen_release_042316.pdf?
The Alzheimer's Association announces a new $4.3 million research grant for a new phase of the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) known as DIAN-TU Next Generation (NexGen). This award will accelerate the testing of new potential Alzheimer’s therapies and a new diagnostic approach in people with genetically based, younger-onset Alzheimer's disease using an innovative trial design that is being applied to Alzheimer’s for the first time. DIAN-TU is a landmark, global Alzheimer's prevention study led by researchers at Washington University in St. Louis.
DIAN-TU NexGen will add the infrastructure for new testing methods and additional drug arms designed to test experimental treatments targeting the accumulation of amyloid brain plaques, a hallmark of Alzheimer's. Amyloid plaques are deposits of the protein fragment amyloid-beta that build up in the spaces between nerve cells and are a hallmark brain change in Alzheimer's.
“This funding will quicken efforts to launch and expand the DIAN-TU NexGen trial, creating the foundation for a new generation of clinical trials. DIAN-TU NexGen will accelerate both the testing of potential therapies and allow for the consideration and execution of combination therapy, which has the potential to make a real impact on those with the disease,” said Maria Carrillo, Ph.D., Alzheimer’s Association Chief Science Officer. “Having a treatment that can delay the onset of Alzheimer's is projected to reduce the number of individuals affected by the disease by 2.5 million within the first five years it is available.”
Making this Award Possible
The Alzheimer’s Association funding for DIAN-TU NexGen is made possible by donations to the Alzheimer’s Association from St. Louis-based financial services firm Edward Jones and Alzheimer’s Association Zenith Society members John and Crystal Beuerlein, of St. Louis, and Mary Barton Smith, of Portola Valley, California. John Beuerlein is General Partner at Edward Jones. The Zenith Society is a group of individuals and organizations that have each committed $1 million or more to the Alzheimer’s Association to support research.